Drug concentration in lung tissue
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To the Editor:
Multidrug-resistant tuberculosis (MDR-TB) is emerging worldwide, with 3.7% of new cases and 20% of previously treated tuberculosis (TB) cases having MDR-TB. Unfortunately, second-line TB drugs, used for MDR-TB treatment, are less effective than first-line drugs 1 .
Sputum culture rather than sputum smear microscopy is recommended to monitor treatment response 1. Therapeutic drug monitoring (TDM), which may help optimize efficacy and minimize side-effects with the potential to safeguard intestinal absorption of drugs 2 , is currently not recommended in World Health Organization (WHO) treatment guidelines 1 .
Although TDM yields information on serum drug concentrations, penetration of secondline TB drugs into diseased tissues such as destroyed lung tissue has, to our knowledge, not been addressed in studies 3 . Herein, we report simultaneous blood and tissue concentrations of second-line TB drugs in lung tissue destroyed by MDR-TB.
A 13-year-old Somalian, HIV sero-negative female, residing in the Netherlands since 2010, was admitted to our TB Unit (TB Center Beatrixoord, University Medical Center Groningen, Groningen, the Netherlands) in September 2011 with a 3-month history of cough, fever, chest pain and unintentional 14 kg weight loss. TB contacts were denied and she had not received a bacilli Calmette-Guérin vaccination. Apart from almost absent breathe sounds and dullness to percussion over the left lung field her physical examination was normal.
Chest radiography showed infiltrates in the left lung, particularly in the left upper lobe.
Sputum microscopy revealed acid-fast bacilli, and she was started on TB treatment with isoniazid, rifampicin, pyrazinamide and ethambutol. 2 weeks later, molecular diagnostic tests revealed mutations in both the katG and rpoB genes. MDR-TB was now considered and she was transferred to our hospital (University Medical Center Groningen).
We changed her treatment to pyrazinamide, ethambutol, kanamycin and moxifloxacin The first sputum microscopy was negative after 6 weeks, and the sputum culture turned negative after 2 months. Afterwards, culture was positive on a further two occasions; at 3 and 5 months after starting treatment. No radiological improvement occurred, with atelectasis of the left upper lobe. We were concerned that the drugs would not penetrate into the affected lung; therefore, surgery was now considered. 99mTc-macroaggregated albumin lung perfusion imaging (Figure 1 ), lung function testing and a computed tomography scan of the chest were performed to evaluate the relative contribution of the left lung for perfusion, and to assess her pulmonary reserve. It was concluded that the left lung hardly contributed to her pulmonary function and a left pneumonectomy was performed.
Immediately Consecutive chest radiographs showed gradual fluid filling of the pleural cavity. Our patient was discharged 2 months after pneumonectomy in a good condition. Her TB treatment regimen was switched to an oral regimen, consisting of co-trimoxazole, moxifloxacin and clofazimine (five times per week, 100 mg) for another 10 months. She has been well, and at the time of writing this report, 4 months before completion of drug therapy, she reported being well with no signs of relapse and no side effects with improved exercise tolerance.
For the first time, we describe blood and tissue concentrations of second-line TB drugs. We showed that drug penetration was excellent, with similar drug concentrations in severely TB-affected lung tissue and in less affected lung tissue. Only one report, an overview by Dartois et al. 3 , has addressed the question of how well second-line TB drugs penetrate into diseased lung and other tissues in relation to TDM but, unlike data on first-line drugs in resected lung tissue, no paired tissue and blood data have been reported on second-line drugs to date. Only data from rabbit models showed that moxifloxacin had a better AUC in lung and lesion tissue relative to plasma AUC compared to the first-line TB drugs 6 . Tailored regimens for MDR-TB treatment can be started after DST results are known.
Efficacy of treatment for MDR-TB is solely based on sputum smear and culture status . Therefore, to date, the full potential of TDM and drug penetration into TBaffected tissues has not been studied.
Surgery added to chemotherapy for MDR-TB has been described in case series but no randomised controlled trials have been conducted to evaluate this approach. In reported series, selection bias by indication is a potential flaw as patients who underwent surgery were perhaps younger or in a better clinical condition. However, even with these limitations, surgical resection has been suggested early in the course of treatment of MDR-TB 8, 9 . A recent meta-analysis showed that the treatment effect of surgery added to chemotherapy was more pronounced in studies with extensively drug-resistant TB. This meta-analysis also showed that the treatment effect was stronger in MDR-TB studies with isolates showing resistance to more than 4.7 drugs 10 .
Surgery added to chemotherapy was widely used in the pre-rifampicin era, even at our center as shown in the thesis of Mulder-De Jong 11 , with 25% of samples being culture positive and 96% positive on microscopy. A limitation in our approach was that we took only one sample per resected lobe.
In our patient a pneumonectomy was performed because we feared that drugs would not reach the most severely affected parts of the destroyed lung, potentially resulting in persistent organisms that might subsequently cause a relapse or treatment failure if sub-therapeutic drug concentrations resulted in additional drug resistance. With a 36-h delay between the last dose of moxifloxacin and linezolid before surgery, both drugs were still detectable equally well. We have shown, although just in one patient, that treatment regimens yielding adequate blood concentrations as evidenced by TDM may provide similarly adequate penetration in affected tissue; non-resolving pulmonary infiltrates in TB patients do not necessarily preclude inadequate drug penetration.
